Table 2.
Cohort HIV and treatment characteristics at enrollment (N=93)
| Characteristic | Value |
|---|---|
| BMI, all, median (IQR) kg | 19.3 (18.0, 21.8) |
| - Female (N=56) | 19.4 (17.9, 21.8) |
| - Male (N=37) | 19.0 (18.0, 21.6) |
| ART history* | |
| - Prior or current first-line regimen | 89 (96) |
| - Prior or current second-line regimen | 42 (45) |
| - Prior or current holding regimen** | 3 (3.2) |
| Duration on ART, median (IQR) years | 6.2 (3.3–10.7) |
| Reasons for second-line switch, N (%) (N=42) | |
| - Treatment failure | 39 (93) |
| - Toxicity | 2 (2.2) |
| - Patient preference | 1 (1.1) |
| Current ART regimen | |
| - PI-based | 39 (42) |
| - NVP-based | 23 (25) |
| - EFV-based | 24 (26) |
| - Others | 5 (5) |
| - Missing | 2 (2) |
| Daily ART pill burden, median (IQR) | 3 (2, 5) |
| Median (IQR) VAS, % | 97 (90,100) |
| Missed ≥1 ART dose in the past 3 months, N (%)*** | 18 (19) |
| - Median (IQR) doses missed | 3 (2, 4) |
| Primary financial responsibility for ART | |
| - National health insurance | 32 (34) |
| - Private, employer or other health insurance | 14 (15) |
| - Social security | 13 (14) |
| - Self-pay | 9 (10) |
| - Do not remember or no answer | 25 (27) |
| Hepatitis B virus vaccine (known), N (%) | 84 (90) |
| Hepatitis B surface antigen | |
| - Negative | 87 (94) |
| - Positive | 5 (5.4) |
| - Not done | 1 (1.1) |
| Hepatitis C virus antibody, N (%) | |
| - Negative | 45 (48) |
| - Not tested, unknown | 48 (52) |
| CD4, median (IQR) cells/mm3 | 601 (477, 800) |
| HIV-RNA ≤40 copies/mL, N (%) | 76 (82) |
| - Log HIV-RNA in those with >40 copies/mL (N=17), median (IQR) | 3.69 (3.54, 4.41) |
| ALT, median (IQR) U/L | 17 (13, 26) |
| Creatinine, median (IQR) mg/dL | 0.75 (0.60, 0.86) |
| Fasting cholesterol, median (IQR) mg/dL | 169 (152, 196) |
| Fasting high-density lipoprotein, median (IQR) mg/dL | 51 (39, 64) |
| Fasting low-density lipoprotein, median (IQR) mg/dL | 98 (80, 117) |
| Fasting triglycerides, median (IQR) mg/dL | 104 (79, 140) |
*
Responses are not mutually exclusive
**
This represents treatment with a non-suppressive regimen during a period of poor adherence (e.g., lamivudine monotherapy)
***
Adherence by self-report
BMI-body mass index; ART-antiretroviral therapy; IQR-interquartile range; PI-protease inhibitor; NVP-nevirapine; EFV-efavirenz; VAS-visual analogue scale. The visual analogue scale is a tool to collect self-reported adherence information on a 0–100 scale (see reference 16, Finitsis DJ, et al, 2016).